Cereno Scientific granted approval from EMA to initiate first-in-human Phase I trial with novel epigenetic HDAC inhibitor, CS014
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the Clinical Trial Application (CTA) for a first-in-human, Phase I trial of novel histone deacetylase inhibitor (HDACi) drug candidate CS014, has been approved by the European Medicines Agency.“Progressing CS014 from preclinical to a clinical stage marks a major achievement of our R&D Team. We look forward to exploring the future treatment possibilities based on the existing properties of the drug”, said Dr. Rahul Agrawal,